Lukas Kirchner

Lukas Kirchner

Auto-generated profile, based on publicly available information

Lukas Kirchner

Institute for Pharmacy and Food Chemistry, University of Wurzburg, 97074 Wurzburg, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

3 December 2024 in ACS Infectious Diseases
Verified
Journal Article
Open access
LKLukas Kirchner
Lukas Kirchner
TMTessa Marciniak
Tessa Marciniak
CEChristine Erk
Christine Erk
WZWilma Ziebuhr
Wilma Ziebuhr
OSOliver Scherf-Clavel
Oliver Scherf-Clavel
UHUlrike Holzgrabe
Ulrike Holzgrabe
Recently, a high-level daptomycin (DAP)-resistant Mammaliicoccus sciuri strain (TS92) was identified, which mediates a 33% decline of DAP when incubated in Mueller-Hinton (MH) medium. The genetic background of the DAP resistance in TS92 is a newly discovered two-gene operon, named drcAB, whose expression was reported to impair the structural integrity of DAP, eventually leading to its inactivation. Here, we set out to elucidate the chemical nature of drcAB-mediated DAP modification by applying a general unknown comparative screening (GUCS) approach in high-resolution mass spectrometry. DAP in MH medium was incubated with Staphylococcus aureus strain RN4220_Pxyl/tet-drcAB, which carries the drcAB operon under control of an inducible promoter on a plasmid, and GUCS test and reference samples were obtained upon and without drcAB expression. A two-step process catalyzed by DrcAB was discovered, comprising a structural alteration of DAP. The mass spectrometric data indicate an N-substitution at the aniline moiety of kynurenine with dehydroalanine and, subsequently, a cleavage of the ester bond of the DAP core between kynurenine and threonine by means of water. The structures postulated were confirmed by comparison of in silico versus measured fragmentation patterns.

30 April 2024 in Archiv der Pharmazie
Verified
Journal Article
Open access
TLTheresa Lohr
Theresa Lohr
NSNicolas Julian Scheuplein
Nicolas Julian Scheuplein
CJChristopher Jenkins
Christopher Jenkins
INIsobel Norville
Isobel Norville
CEChristine Erk
Christine Erk
UHUlrike Holzgrabe
Ulrike Holzgrabe
Due to increasing antibiotic resistance, the development of anti‐infectives with new mechanisms of action is crucial. Virulence factors such as the “macrophage infectivity potentiator” (Mip) protein, which catalyzes the folding of proline‐containing proteins by means of their cis–trans isomerase (PPIase) activity, have come into focus as a potential new target. Since the inhibition of Mip by small molecules has been shown to lead to reduced virulence and survival in vitro, especially of Gram‐negative bacteria such as Burkholderia pseudomallei (Bp), Neisseria meningitidis (Nm), and Neisseria gonorrhoeae (Ng), or Coxiella burnetii (Cb), among many others, a library of Mip inhibitors was developed. As drug metabolism has a significant impact on the overall therapeutic outcome, this report describes the biotransformation of the most potent Mip inhibitors. Therefore, the anti‐infectives were treated using human liver microsomes in vitro. Liquid chromatography with tandem mass spectrometry (LC/MS‐MS) methods were applied to identify the metabolites and quantify the metabolic degradation of the hit compounds. Active metabolites, N‐oxides, were found, leading to new opportunities for further drug development.

18 August 2023 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
LKLukas Kirchner
Lukas Kirchner
TMTessa Marciniak
Tessa Marciniak
WZWilma Ziebuhr
Wilma Ziebuhr
OSOliver ScherfClavel
Oliver ScherfClavel
UHUlrike Holzgrabe
Ulrike Holzgrabe

7 August 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
LKLukas Kirchner
Lukas Kirchner
TMTessa Marciniak
Tessa Marciniak
CEChristine Erk
Christine Erk
WZWilma Ziebuhr
Wilma Ziebuhr
OSOliver Scherf-Clavel
Oliver Scherf-Clavel
UHUlrike Holzgrabe
Ulrike Holzgrabe
Recently, a high-level daptomycin (DAP) resistant Mammaliicoccus sciuri strain (TS92) was identified which mediates a 33 percent decline of DAP when incubated in Mueller-Hinton (MH) medium. The genetic background of the DAP resistance in TS92 is a newly discovered two-gene operon, named drcAB, whose expression was reported to impair the structural integrity of DAP, eventually leading to its inactivation. Here we set out to elucidate the chemical nature of drcAB-mediated DAP modification by applying a general unknown comparative screening (GUCS) approach in high-resolution mass spectrometry. DAP in MH medium was incubated with Staphylococcus aureus strain RN4220_Pxyl/tet-drcAB, which carries the drcAB operon under control of an inducible promotor on a plasmid, and GUCS test and reference samples were obtained upon and without drcAB expression. A two-step process catalyzed by DrcAB was discovered, comprising a structural alteration of DAP. The mass spectrometric data indicate an N-substitution at the aniline moiety of kynurenine with dehydroalanine, and subsequently, a cleavage of the ester bond of the DAP core between kynurenine and threonine by means of water. The structures postulated were confirmed by comparison of in silico versus measured fragmentation patterns.